VYNE Therapeutics Inc.
VYNE Therapeutics Inc. (VYNE) Stock Overview
Explore VYNE Therapeutics Inc.’s financial performance, market position, analyst ratings, and future outlook.
VYNE Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of VYNE Therapeutics Inc. (VYNE) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $0.89.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -1.59 and a market capitalization of 27M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Analyst Recommendations
Price Targets
Company Profile
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Mr. David T. Domzalski
13
520 U.S. Highway 22, Bridgewater, NJ
2018